Drug combo safety check: early study completed

NCT ID NCT06717100

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial studied how deupirfenidone (LYT-100) and nintedanib interact in 24 healthy adults aged 18-65. Participants took both drugs over several weeks to measure drug levels and check for side effects. The goal was to understand potential drug-drug interactions, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

deupirfenidone (LYT-100) and nintedanib

What this could lead to

If successful, this study could help determine safe dosing when combining these two drugs for future treatments.

What could go wrong

This is a very early, small study in healthy volunteers, not patients. Results may not predict real-world effects or safety in people with disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG INTERACTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nucleus Network Pty Ltd (Commercial Rd and St Kilda Rd) - VIC

    Melbourne, Victoria, 3004, Australia